Role of radiotherapy in melanoma management

Radiology and Oncology

Volumn 44, Issue 1, 2010, Pages 1-12

  Strojan, Primoz ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Fractionation; Indications; Melanoma; Radiobiology; Radiotherapy; Toxicity

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PALLIATIVE THERAPY; PROGNOSIS; RADIATION DOSE FRACTIONATION; RADIOBIOLOGY; REVIEW; TREATMENT INDICATION;

EID: 77950118291     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-010-0008-x     Document Type: Review

References (81)

1. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilization in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-126
2. Cancer incidence in Slovenia 1997. Report no. 39. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia; 2000.
3. Cancer incidence in Slovenia 2006. Report no. 48. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia; 2009.
4. Kingham TP, Karakousis G, Ariyan C. Randomized clinical trials in melanoma. Surg Oncol Clin N Am 2010; 19: 13-31.
5. Paterson R. Classification of tumours in relation to radiosensitivity. Br J Radiol 1933; 6: 218-233
6. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for melanoma. A review of the evidence. Cancer 2004; 100: 1293-1301
7. Overgaard J, Overgaard M, Hansen V, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986; 5: 183-192
8. Bentzen SM, Overgaard J, Thames HD, Overgaard M, Hansen PV, von der Maase H, et al. Clinical radiobiology of malignant melanoma. Radiother Oncol 1989; 16: 169-182
9. Rofstad EK, Wahl A, Tveit KM, Monge OR, Brustad T. Survival curves after X-ray and heat treatments for melanoma cells derived directly from surgical specimens of tumours in man. Radiother Oncol 1985; 4: 33-44.
10. Bentzen SM, Thames HD, Overgaard J. Does variation in the in vitro cellular radiosensitivity explain the shallow clinical dose-control curve for malignant melanoma? Int J Radiat Biol 1990; 57: 117-126
11. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells frown in vitro. Cancer Res 1971; 31: 830-833
12. McKay MJ, Kefford RF. The spectrum of in vitro radiosensitivity in four human melanoma cell lines is not accounted for by differential induction or rejoining of DNA double strand breaks. Int J Radiat Oncol Biol Phys 1995; 31: 345-352
13. Trott KR. The optimal radiation dose per fraction for the treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 1991; 20: 905-907
14. Jones B, Dale RG, Deehan C, Hopkins KI, Morgan DA. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol) 2001; 13: 71-81.
15. Rofstad EK, Mathiesen B, Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxiainduced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res 2004; 64: 13-18
16. Rofstad EK. Fractionation sensitivity (a/b ratio) of human melanoma xenografts. Radiother Oncol 1994; 33: 133-138
17. Bello MT, Ang KK. Radiation therapy for malignant melanoma. Surg Clin N Am 2003; 83: 323-342
18. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991; 20: 429-432
19. Dvořák E, Haas RE, Liebner EJ. Contribution of radiotherapy to the management of malignant melanoma. A ten year experience at the University of Illinois Hospital in Chicago. Neoplasma 1993; 40: 387-399
20. Fenig E, Eidelevich E, Njuguna E, Katz A, Gutman H, Sulkes A, Schechter J. Role of radiation therapy in the management of cutaneous malignant melanoma. Am J Clin Oncol 1999; 22: 184-186
21. Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006; 66: 1051-1055
22. Strojan P, Jančar B, Čemažar M, Pohar Perme M, Hočevar M. Melanoma metastases to the neck: role of adjuvant irradiation. Int J Radiat Oncol Biol Phys. In press.
23. Corry J, Smith JG, Bishop M, Ainslie J. Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys 1999; 44: 1065-1069
24. Burmeister BH, Smithers BM, Burmeister E, Baumann K, Davis S, Krawitz, et al. A Prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma - Trans Tasman Radiation Oncology Group (TROG) study 96.06. Radiother Oncol 2006; 81: 136-142
25. Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys 1985; 11: 1837-1839
26. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, et al. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 1995; 345: 795-798
27. Harwood AR. Conventional fractionation radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys 1983; 9: 1019-1021
28. Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, Wendtner CM, Peter RU, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43: 477-482
29. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146: 1042-1046
30. Krengli M, Jereczek-Fossa BA, Kaanders JHAM, Masini L, Beldì D, Orecchia R. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit Rev Oncol Hematol 2008; 65: 121-128
31. Trotty A, Peters LJ. Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Sem Surg Oncol 1993; 9: 246-250
32. Krengli M, Masini L, Kaanders JHA, Maingon P, Oei SB, Zouhair A, et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006; 65: 751-759
33. Leon P, Daly JM, Synnestvedt M, Schultz DJ, Elder DE, Clark WH. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991; 126: 1461-1468
34. Kelly JW, Sagebiel RW, Calderon W, Murillo L, Dakin RL, Blois MS. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984; 200: 759-763
35. Posther KE, Selim MA, Mosca PJ, Stanley WE, Johnson JL, Tyler DS, et al. Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann Surg Oncol 2006; 13: 728-739
36. Jaroszewski DE, Pockaj BA, DiCaudo DJ, Bite U. The clinical behavior of desmoplastic melanoma. Am J Surg 2001; 182: 590-595
37. Vongtama R, Safa A, Gallardo D, Calcaterra T, Juillard G. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck 2003; 25: 423-428
38. Quinn MJ, Crotty KA, Thompson JF, Coates AS, O'Brien CJ, McCarthey WH. Desmoplastic and desmoplastic neutropic melanoma: experience with 280 patients. Cancer 1998; 83: 1128-1135
39. Arora A, Lowe L, Su L, Rees R, Bradford C, Cimmino VC, et al. Wide excision without radiation for desmoplastic melanoma. Cancer 2005; 104: 1462-1467
40. Johanson CR, Harwood AR, Cummings BJ, Quirt I. 0-7-21 radiotherapy in nodular melanoma. Cancer 1983; 51: 226-232
41. Cooper JS, Chang WS, Oratz R, Shapiro RL, Roses DF. Elective radiation therapy for high-risk malignant melanoma. Cancer J 2001; 7: 498-502.
42. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999; 44: 607-618
43. Creagan ET, Cupps RE, Ivins JC, Pritchard DJ, Sim FH, Soule EH, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer 1978; 42: 2206-2210
44. Henderson MA, Burmeister B, Thompson JF, Di Iulio J, Fisher R, Hong A, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). [Abstract]. J Clin Oncol 2009; 27 (Suppl): LBA9084.
45. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989; 124: 1051-1055
46. Singletary SE, Byers RM, Shallenberger R, McBride CM, Guinee VF. Prognostic factors in patients with regional cervical nodal metastases from cutaneous malignant melanoma. Am J Surg 1986; 152: 371-375
47. O'Brien CJ, Petersen-Schaefer K, Stevens GN, Stevens GN, Bass PC, Tew P, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997; 19: 589-594
48. Monsour PD, Sause WT, Avent JM, Noyes RD. Local control following therapeutic nodal dissection for melanoma. J Surg Oncol 1993; 54: 18-22.
49. Miller EJ, Daly JM, Synnestvedt M, Schultz D, Elder D, Guerry D. Locoregional nodal relapse in melanoma. Surg Oncol 1992; 1: 333-340
50. Lee RJ, Gibbs JF, Proulx GM, Kollmorgen DR, Jia C, Kraybill WG. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000; 46: 467-474
51. Shen P, Wanek LA, Morton DL. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol 2000; 7: 554-559
52. Pidhorecky I, Lee RJ, Proulx G, Kollmorgen DR, Jia C, Driscoll DL, et al. Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol 2001; 8: 109-115
53. Bowsher WG, Taylor BA, Hughes LE. Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg 1986; 73: 906-908
54. Bayers RM. The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck. Arch Surg 1986; 121: 1338-1341
55. Kretschmer L, Preusser KP. Standardized axillary lymphadenectomy improves local control but not survival in patients with palpable lymph node metastases of cutaneous malignant melanoma. Langenbeck Arch Surg 2001; 386: 418-425
56. Kissin MW, Simpson DA, Easton D, White H, Westbury G. Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma. Br J Surg 1987; 74: 1023-1026
57. Hughes TMD, A'Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg 2000; 87: 892-901.
58. Kretschmer L, Neumann C, Preußer KP, Marsch WC. Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin. Acta Oncol 2001; 40: 72-78
59. Allan CP, Hayes AJ, Thomas JM. Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin. ANZ J Surg 2008; 78: 982-986
60. Meyer T, Merkel S, Göhl J, Hohenberger W. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. Eur J Surg Oncol 2002; 28: 424-430
61. Agrawal S, Kane JM, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009; 115: 5836-5844
62. Ang KK, Peters LJ, Weber RS, Morrison WH, Frankenthaler RA, Garden AS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30: 795-798
63. Ballo MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 2003; 97: 1789-1796
64. Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002; 52: 964-972
65. Beadle BM, Guadagnolo BA, Ballo MT, Lee JE, Gershenwald JE, Cormier JN, et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2009; 73: 1376-1382
66. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 2004; 11: 1079-1084
67. Burmeister BH, Smithers BM, Poulsen M, McLeod GR, Bryant G, Tripcony L, et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995; 19: 369-371
68. Stevens G, Thompson JF, Firth I, O'Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000; 88: 88-94.
69. Fuhrmann D, Lippold A, Borrosch F, Ellwanger U, Garbe C, Suter L. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? Br J Dermatol 2001; 144: 66-70.
70. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 2006; 64: 106-113
71. Moncrieff MD, Martin R, O'Brien CJ, Shannon KF, Clark JR, Gao K, et al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients? Ann Surg Oncol 2008; 15: 3022-3027
72. Ballo MT, Garden AS, Myers JN, Lee JE, Diaz Jr EM, Sturgis EM, et al. Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck 2005; 27: 718-721
73. Bonnen MD, Ballo MT, Myers JN, Garden AS, Diaz JREM, Gershenwald JE, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004; 100: 383-389
74. Rofstad EK. Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma. Cancer Res 1992; 52: 4453-4457
75. Gojkovič Horvat A, Kovač V, Strojan P. Radiotherapy in palliative treatment of painful bone metastases. Radiol Oncol 2009; 43: 213-224
76. Majer M, Samlowski W. Management of metastatic melanoma patients with brain metastases. Curr Oncol Rep 2007; 9: 411-416
77. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22: 1293-1300
78. Gaudy-Marqueste C, Regis JM, Muracciole X, Laurans R, Richard MA, Bonerandi JJ, et al. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65: 809-816
79. Rades D, Kueter JD, Pluemer A, Veninga T, Schild SE. A matched-pair analysis comparing whole-brain radiotherapy plus stereotactic radiosurgery versus surgery plus whole-brain radiotherapy and a boost to the metastatic site for one or two brain metastases. Int J Radiat Oncol Biol Phys 2009; 73: 1077-1081
80. Rajer M, Kovač V. Malignant spinal cord compression. Radiol Oncol 2008; 42: 23-31.
81. Klimo P, Kestle JRW, Schmidt MH. Clinical trials and evidence-based medicine for metastatic spinal disease. Neurosurg Clin N Am 2004; 14: 549-564